Optimal Duration for Clopidogrel Suspension Prior to Coronary Artery Bypass Grafting

  • Ullah W
  • Cheema M
  • Haq S
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Background: American College of Cardiology (ACC) guidelines suggest clopidogrel (Plavix) suspension for 5 days before non-emergent cardiac surgery (class IIa, level B). It puts the patients with recent angioplasty and ongoing ischemia at a higher risk of stent thrombosis. We sought to determine the bleeding risk in patients who stopped clopidogrel at 3 and less than 3 days before coronary artery bypass grafting (CABG) as compared to the usual 5 days prior to CABG.

Cite

CITATION STYLE

APA

Ullah, W., Cheema, M. A., Haq, S., Abdullah, H. M., Ahmad, A., & Cohen, M. (2019). Optimal Duration for Clopidogrel Suspension Prior to Coronary Artery Bypass Grafting. Cardiology Research, 10(2), 74–82. https://doi.org/10.14740/cr842

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free